SpineGuard Reports Q3 Revenue Decline Amid U.S. Model Shift…

Event summary

SpineGuard's Q3 2026 revenue declined 14% YoY to €662K due to a U.S. sales model transition.
Unit sales rose 22% YoY to 1,398, with Europe accounting for 46% of sales.
U.S. revenue dropped 39% YoY to $334K, but unit sales increased 7% YoY.
International revenue grew 25% YoY to €377K, driven by new distributors in the UK, Croatia, and Turkey.
Company aims for operational breakeven in Q4 2026 with €882K cash position as of September 30, 2026.

The big picture

SpineGuard's Q3 results reflect the challenges of transitioning to a distribution model in the U.S., offset by strong international growth. The company's focus on cost control and strategic partnerships aims to position it for operational breakeven amid a competitive medical device landscape. The shift to distribution networks highlights the trade-offs between revenue recognition and market penetration.

What we're watching

Partnership Execution: Whether SpineGuard can sustain U.S. growth through Omnia Medical's distribution network.
Operational Breakeven: The pace at which SpineGuard achieves cost-control goals to reach Q4 operational breakeven.
International Expansion: How new distributors in emerging markets impact revenue growth outside the U.S. and Europe.